Treatment

3 Things That Keep You Sick

makeover your healthHey, I would like to share a very important message with you.

The gluten-free diet is the main treatment for gluten sensitivity and celiac disease. However, removing gluten is not the only thing we must do to regain our health.

Here are the top three things people miss when they go gluten-free. You must do these things in order to achieve good health:

  1. Reduce Inflammation

Inflammation is one of the main causes of disease. In celiac disease and gluten sensitivity, gluten is regarded as the trigger for inflammation. However, inflammation may persist if gluten has caused a dysfunction that is now triggering its own Read More »

Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study

 

PRESS RELEASE
Milestone Marks the First Time a European Patient with Active Celiac Disease has Enrolled in a Clinical Trial for an Investigational Medication from Alba Therapeutics
Last update: 8:22 p.m. EST Nov. 11, 2008
BALTIMORE, Nov 11, 2008 /PRNewswire via COMTEX/ —

Alba Therapeutics Corporation announced today that for the first time, a European patient with active celiac disease has been enrolled in its clinical trial to investigate a treatment for the disease. Alba has enrolled and randomized the newly diagnosed patient from Spain in an eight-week Phase IIb trial with oral larazotide acetate, a tight junction regulator, for the treatment of patients with active celiac disease (CD). The global multi-center, randomized, double-blind, placebo-controlled study will evaluate the clinical and histological efficacy, safety and tolerability of larazotide acetate in 106 active CD subjects adhering to a gluten-free diet, while assessing improvement in the clinical signs and symptoms of celiac disease.

“These are decisive times for our desire to one day be able to offer our celiac patients a treatment that allows them to live more normal lives,” said Dr. Gemma Castillejo, MD, a pediatric gastroenterologist and principal investigator in the study. Dr. Castillejo, a leading European celiac expert from the Sant Joan de Reus University Hospital in Reus, Spain added, “I believe this clinical trial has the potential to be a turning point in the search for treatments for celiac disease.”
“This is a major milestone for the celiac community in Europe,” stated Francisco Leon, MD, PhD, Vice President, Clinical Development and Medical Affairs of Alba. “This is Alba’s sixth human trial with larazotide acetate, and we are excited to be advancing our investigational program for larazotide acetate in this important region of the world.”
About Celiac Disease
Celiac disease is an inherited autoimmune disorder where gluten has been identified as the environmental trigger of the disease. Gluten is an ingested protein found in wheat, barley and rye. Gluten is broken down into gliadin which can pass through the intestinal epithelial barrier during times of increased intestinal permeability. The ingestion of gluten causes an immune response which triggers an inflammatory reaction in the small intestine. This then causes damage to the villi in the small intestine and can lead to total villous atrophy in celiac disease. This results in varying symptoms such as fatigue, skin rash, anemia, fertility issues, joint pain, weight loss, pale sores inside the mouth, tooth discoloration or loss of enamel, depression, chronic diarrhea or constipation, gas and abdominal pain. The immunology and nutritional abnormalities in celiac disease can potentially result in long- term complications such as osteoporosis, refractory sprue, small intestinal cancer, and lymphoma.
Celiac disease is a growing public health concern, affecting approximately 3 million people in the United States and over 6.5 million people worldwide. The only current management of celiac disease is complete elimination of gluten from the diet, which can be very difficult to implement in practice. Additionally, the response to the gluten-free diet is poor in up to 30% of patients, and dietary nonadherence is the chief cause of persistent or recurrent symptoms.(1)
(1) Green, P, and Cellier, C, Review Article,
 Medical Progress, Celiac Disease, N ENGL J MED
 2007;357:1731-43
About “Larazotide Acetate”
Larazotide acetate is an experimental medicine and a tight junction regulator that acts locally by inhibiting the opening of tight junctions in epithelial cells lining the small intestine. In celiac disease, gluten crosses the epithelial barrier and stimulates the immune system, leading to cytokine release, gut inflammation, and opening of tight junctions. This leads to increased paracellular permeability, increased entry of gluten and the establishment of an intestinal permeability-inflammation loop. Larazotide acetate inhibits tight junction opening triggered by both gluten and inflammatory cytokines, thus reducing uptake of gluten. Larazotide acetate disrupts the intestinal permeability-inflammation loop, and reduces symptoms associated with celiac disease. Larazotide acetate is orally formulated, has been granted “Fast Track” designation by the U.S. Food and Drug Administration for the treatment of celiac disease, and is also being evaluated for the treatment of Crohn’s Disease.

For more information about Alba’s clinical trials, please visit the www.clinicaltrials.gov web site and search for Alba Therapeutics.

About Alba
Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to treat autoimmune and inflammatory diseases and is located in Baltimore, Maryland. Alba’s technology platform is based upon a key pathway that regulates the assembly and disassembly of tight junctions in cell barriers throughout the body. As a result of its unique technology platform, Alba is a leader in mucosal biology and has developed a pipeline of innovative therapeutic candidates that has the potential to modify the course of disease and significantly improve upon existing treatments for a wide range of diseases such as celiac disease, Crohn’s disease, and Asthma/COPD or acute lung injury.
    Media: Mariesa Kemble
    Sam Brown Communications
    608-850-4745
    kemblem@aol.com 

    Corporate: Wendy Perrow, MBA
    Alba Therapeutics Corporation
    410-878-9850
    info@albatherapeutics.com
    http://www.albatherapeutics.com
----------------------
Author Information: John Libonati, Philadelphia, PA
Publisher, Glutenfreeworks.com.
Editor & Publisher, Recognizing Celiac Disease.
John can be reached by e-mail here.

Americans Spend Over $25 Billion Each Year on 8 Pharmaceutical Drugs That Deplete Nutrients

 

Lipitor raked in more than $5 billion for pharmaceutical giant, Pfizer Inc., during 2009 according to Drugs.com

Nexium Depletes Nutrients

Are drugs making you sick?

Sales of the 5 leading drugs for mental disorders topped $12,750,023,000, while Nexium and Prevacid totaled 7,523,382,000.

All eight of these drugs deplete nutrients. 

 

Revenues of the Top 8 Selling Drugs of 2009

Lipitor: lowers cholesterol – $5,363,193,000

Nexium: acid reducer – $5,014,827,000

Prevacid: acid reducer – $2,508,555,000

Seroquel: antipsychotic – $3,117,591,000 Read More »

Avaxia Biologics Awarded Patent for Celiac Disease Treatment Pill

John Libonati Gluten Free Works

LEXINGTON,  Mass., Dec. 13, 2011 /PRNewswire/ — Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,071,101, “Antibody Therapy for Treatment of Diseases Associated With Gluten Intolerance.”

This patent, which expires on May 27, 2029, provides broad coverage for treating celiac disease using Read More »

Be Healthier in 2010 with Celiac Disease Manual: Save $10.00 Until Jan 8th

recognizing_celiac_disease_website_cover_132x162Libonati_John_Philadelphia_PA

Gluten Free Works Publishing is helping people with celiac disease kick off a healthier 2010 by offering a $10.00 discount on the highly recommended celiac disease manual, “Recognizing Celiac Disease,” now through January 8th.

Recognizing Celiac Disease” is the ready celiac reference that thousands of people are using to get well and stay healthy.

“Recognizing Celiac Disease” lists over 300 symptoms of celiac disease and the nutrient deficiencies that cause them both before and after diagnosis. This comprehensive reference will help you understand gluten sensitivity, celiac disease, nutrient deficiencies and how they are affecting you so you can correct them and heal.

Doctors, dietitians, marines, chefs, hairdressers and celiac support groups across the country are using this invaluable tool. You can find dozens of reader letters on the Recognizing Celiac Disease website. Some are touching, some are amazing, but all of them rave about this fantastic resource and the information it gave them that helped them get better and monitor their health.

The list of experts from the most prestigious medical institutions who recommend the work is truly impressive. You can see them here.

“This masterful, comprehensive and easy-to-use resource guide will go a long way in helping folks restore their health and regain their lives, a goal we share. Recognizing Celiac Disease has a permanent place on my desk and I definitely will recommend this well-researched reference manual to healthcare professionals and patients alike.”

-Alice Bast, Founder and Executive Director,
National Foundation for Celiac Awareness

Take advantage of this limited time offer and get your own copy now. You will be happy you did…

Click here for more information and to order Recognizing Celiac Disease.

————————-
“Author Information: John Libonati, Philadelphia, PA
Publisher, Glutenfreeworks.com.
Editor & Publisher, Recognizing Celiac Disease.
John can be reached at john.libonati@glutenfreeworks.com.”

BioLineRX’s BL-7010 Treatment of Celiac Disease and Gluten Sensitivity Presented

biolinerx celiac disease therapy

BioLineRx Therapy BL – 7010 Treats Celiac Disease & Gluten Sensitivity

BioLineRx Ltd, a biopharmaceutical development company, was invited to deliver an oral presentation at the recent 2013 National Education Conference & Gluten-Free Expo, the Celiac Disease Foundation’s annual conference, in Pasadena, California.

Leah Klapper, Ph.D., General Manager, BioLine Innovations Jerusalem, presented BioLineRx’s therapy, BL-7010, for the treatment of celiac, as part of a session entitled Breaking Therapies Beyond the Gluten-Free Diet.

BL-7010 will be presented at Read More »

Celiac Disease Alert: Six Ways Gluten Can Kill You

“I only cheat once in awhile. You know, like twice a week…”

Photo: Suite101.com

If you have celiac disease, you damage your body EVERY TIME you ingest gluten. That may sound bad, but it gets worse.

You can DIE from celiac disease in a variety of ways. None of them are fun. Some take longer than others. Some may not kill you per se, but rather they may stop you from enjoying life, make you suffer from chronic pain or limit your potential.

Celiac disease is a deadly serious condition caused by eating what is essentially a poison to susceptible people – gluten proteins in wheat, barley, rye and oats.

Here are just 6 examples how celiac disease from gluten ingestion can kill you: Read More »

Celiac Disease and Gluten Free Diet Educational Videos

Cheryl Harris Gluten Free Works

Finding out you have Celiac Disease is a big transition. Often it’s a good one that leads to feeling great, yet initially it’s a lot of information to take in at once to understand what you need to do for your health. Much of it is because we’re been eating one way for 15, 30, 50 or more years and it can be overwhelming to to instantly unlearn everything we’ve done and change overnight. Wouldn’t life be easier if you could take a doctor or dietitian home as a portable reminder of the basics? And so the Celiac Disease Video Project was born.

See below for videos of Dr. John Snyder, Chief of the Department of Gastroenterology at CNMC in DC, Dr. Gary Kaplan, Medical Director of Kaplan Center for Integrative Medicine and Cheryl Harris, MPH, RD Registered Dietitian and Nutritionist discussing testing, diagnosis and follow-up, eating a gluten-free diet and a short segment on when it’s not Celiac. Though there are an increasing number of videos out there on people’s stories of diagnosis and ways to make a gluten-free pie, this is the first of its kind to do a run-down of the medical and diet basics by healthcare professionals. The Celiac Sprue Association has been kind enough to support the project. Read More »

Celiac Disease: Why You Must Depend on Yourself to Be Healthy

Below is an important letter by Cleo Libonati, celiac disease author and speaker. She explains why you must be your own health advocate if you wish to be healthy and receive optimal care.

Dear Friend,

For the past three years, I have met with HMOs, pharmaceutical companies, politicians, doctors, dietitians, celiac support groups, and patients across the United States. One thing is abundantly clear. Doctors are not recognizing celiac disease and do not realize how little they know about the disorder.

In 2004, the National Institutes of Health called for education of physicians and other healthcare providers about celiac disease. To date, few efforts have been undertaken and none has succeeded.

The result is missed diagnoses, inadequate follow-up, unnecessary surgeries, improperly prescribed medications and needless pain. During my presentations, I meet many people who think they are receiving good treatment and cannot understand why no one has told them their persisting symptoms are due to simple nutrient deficiencies. Read More »

Domino’s Pizza, Celiac Disease Experts and Defining What Is REALLY Gluten-Free

what is gluten free

Is Food That Contains Gluten Really Gluten-Free?

Domino’s Pizza recently announced it would offer gluten-free pizza for gluten sensitive customers. Domino’s made it clear that the pizzas used a gluten-free crust, but are manufactured using the same equipment as the other gluten-containing foods and are not safe for people with celiac disease.

Domino’s worked with the National Foundation for Celiac Awareness (NFCA) and received the NFCA’s new, and now suspended, “Amber Designation.” This designation was to tell people that although the ingredients are gluten-free, the product cannot claim that cross contamination does not occur. The “Amber Designation” differed from the NFCA’s existing “Green Designation,” which tells the customer that the product is tested to less than 10 parts per million of gluten. “Amber” was basically a caution sign.

What Did Gluten-Free Watchdog Organizations Say?

  • The Gluten Intolerance Group (GIG) and other organizations called for a recall of the NFCA’s “Amber Designation.”
  • The North American Society for the Study of Celiac Disease commented on Domino’s Pizza ‘Gluten-Free’ Crust Announcement as follows,

Read More »

>